Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.

Hegewisch-Becker, Susanna; Nöpel-Dünnebacke, Stefanie; Hinke, Axel; Graeven, Ullrich; Reinacher-Schick, Anke; Hertel, Jan; Lerchenmüller, Christian A; Killing, Birgitta; Depenbusch, Reinhard; Al-Batran, Salah-Eddin; Lange, Thoralf; Dietrich, Georg; Tannapfel, Andrea; Arnold, Dirk

Hegewisch-Becker, Susanna; Nöpel-Dünnebacke, Stefanie; Hinke, Axel; Graeven, Ullrich; Reinacher-Schick, Anke; Hertel, Jan; Lerchenmüller, Christian A; Killing, Birgitta; Depenbusch, Reinhard; Al-Batran, Salah-Eddin; Lange, Thoralf; Dietrich, Georg; Tannapfel, Andrea; Arnold, Dirk.

Afiliación

Hegewisch-Becker S; HOPE - Practice for Oncology, Hamburg, Germany.
Nöpel-Dünnebacke S; Division of Hematology, Oncology and Palliative Care, Medical Department, St Josef-Hospital, Ruhr University, Bochum, Germany.
Hinke A; CCRC, Düsseldorf, Germany. Electronic address: axel.hinke@hotmail.de.
Graeven U; Kliniken Maria Hilf GmbH, Department of Hematology, Oncology and Gastroenterology, Mönchengladbach, Germany.
Reinacher-Schick A; Division of Hematology, Oncology and Palliative Care, Medical Department, St Josef-Hospital, Ruhr University, Bochum, Germany.
Hertel J; Division of Hematology, Oncology and Palliative Care, Medical Department, St Josef-Hospital, Ruhr University, Bochum, Germany.
Lerchenmüller CA; Practice for Oncology, Münster, Germany.
Killing B; Department of Hematology/Oncology, Lahn-Dill-Kliniken, Wetzlar, Germany.
Depenbusch R; Practice for Oncology, Gütersloh, Germany.
Al-Batran SE; Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany.
Lange T; Asklepios Klinikum, Department for Hematology/Oncology, Weißenfels, Germany.
Dietrich G; Department of Gastroenterology/Hematology/Oncology, Klinikum Bietigheim, Bietigheim-Bissingen, Germany.
Tannapfel A; Institute for Pathology, Ruhr University, Bochum, Germany.
Arnold D; Department of Hematology and Medical Oncology, Asklepios Klinik Altona, Hamburg, Germany.

Eur J Cancer ; 101: 105-113, 2018 09.

Article en En | MEDLINE | ID: mdl-30036739

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Colon/efectos de los fármacos; Neoplasias Colorrectales/tratamiento farmacológico; Recto/efectos de los fármacos; Adulto; Anciano; Anciano de 80 o más Años; Bevacizumab/administración & dosificación; Colon/metabolismo; Colon/patología; Neoplasias Colorrectales/genética; Femenino; Humanos; Estimación de Kaplan-Meier; Quimioterapia de Mantención; Masculino; Persona de Mediana Edad; Mutación; Oxaliplatino/administración & dosificación; Pronóstico; Proteínas Proto-Oncogénicas B-raf/genética; Recto/metabolismo; Recto/patología; Estudios Retrospectivos; Adulto Joven; Proteínas ras/genética

Palabras clave

BRAF mutation; Bevacizumab; Colorectal cancer; First-line therapy; Overall survival; Primary tumour location; Prognostic factors; RAS mutation

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Recto / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Colon Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google